StockMarketWire.com - Clinical AI technology group Sensyne Health said it would collaborate with the University of Oxford for which it would provide software for Covid-19 treatment trial.

Sensyne Health said the software would support remote data collection and analytics for a clinical trial of the anti-TNF drug adalimumab to prevent respiratory failure due to Covid-19.

The trial was funded by the Covid-19 Therapeutics Accelerator, an initiative set up by the Wellcome Trust, the Bill and Melinda Gates Foundation and Mastercard, with support from public and philanthropic donors.


At 1:22pm: [LON:SENS] Sensyne Health Plc Ord 10p share price was -5.5p at 55p



Story provided by StockMarketWire.com